Rakovina Therapeutics Advances Novel AI-Discovered PARP1 and ATR Inhibitors for Hard-to-Treat Cancers
Key Insights
Rakovina Therapeutics (search) presented preclinical data at AACR 2025 showcasing AI-discovered PARP1 (search) inhibitors with improved metabolic stability and potential CNS penetration for brain malignancies.
The company's ATR inhibitor program, developed with Variational AI (search), has identified candidates designed to cross the blood-brain barrier—addressing a critical gap as no FDA-approved ATR inhibitors currently exist.
Using proprietary AI platforms Deep Docking and Enki, Rakovina screened billions of molecules in months rather than years, significantly accelerating the drug discovery process for DNA damage response inhibitors.
Rakovina Therapeutics (search) Inc. (TSX-V: RKV) presented promising new preclinical data from two of its lead programs at the American Association for Cancer (search) Research (AACR) Annual Meeting 2025, demonstrating significant progress in its AI-powered cancer drug discovery platform.
The Vancouver-based biopharmaceutical company showcased results from its PARP1 (search)-selective inhibitor program, which utilized proprietary Deep Docking and generative AI platforms to screen more than four billion potential drug-like molecules. This massive virtual screening identified top candidates that were subsequently synthesized and evaluated at Rakovina's laboratory facilities at the University of British Columbia.
Novel PARP1 Inhibitors Show Superior Pharmacokinetic Profile
The PARP1 (search) inhibitor candidates demonstrated significantly improved metabolic stability compared to existing compounds, featuring the lowest in vitro clearance rates and longest half-life among competitors currently in development. Early animal studies revealed strong plasma exposure and pharmacokinetic properties suggesting central nervous system (CNS) penetration—a potentially crucial advantage for treating brain tumors (search) and metastases.
"Our ability to screen billions of molecules and advance top candidates to in vitro and in vivo validation within months—rather than years—exemplifies the transformative power of AI in drug discovery," said Jeffrey Bacha, Executive Chairman of Rakovina Therapeutics (search). "This acceleration gives us the opportunity to significantly reduce the time and cost required to bring new life-saving cancer (search) treatments to patients."
ATR Inhibitor Program Addresses Critical Treatment Gap
The second presentation highlighted Rakovina's ATR-specific inhibitor program, developed in partnership with Variational AI (search). Researchers identified a focused set of lead candidates predicted to be highly potent and selective against ATR (ataxia telangiectasia and Rad3 related), a key DNA damage response target.
These ATR inhibitor candidates are specifically designed with the potential to cross the blood-brain barrier, addressing a significant unmet need in cancer (search) treatment. Despite the therapeutic potential of ATR inhibitors for cancers with DNA repair deficiencies—including ovarian, breast, and prostate cancers—no FDA-approved treatments currently exist in this category.
The company recently received its first synthesized batch of AI-generated ATR inhibitor compounds, which will now move into preclinical testing at Rakovina's integrated wet lab for further evaluation and validation.
AI-Driven Approach Transforms Drug Discovery Timeline
Rakovina's approach integrates proprietary AI platforms Deep Docking™ and Enki™, enabling the rapid screening of billions of molecular compounds at approximately 100 times the speed of traditional methods. This technological advantage has significantly reduced the time and cost of preclinical drug discovery, offering a competitive edge in the DNA damage response (DDR) therapeutics market, which is projected to reach $18 billion by 2030.
Dr. Mads Daugaard, President and Chief Scientific Officer of Rakovina, emphasized the transformative nature of their approach: "What we're seeing with Rakovina's AI-enabled pipeline is the future of oncology—faster, smarter, and more precise. This integration of generative AI and biological insight is transforming how—and how quickly—we can identify and advance new therapies."
Market Context and Future Direction
The global market for PARP inhibitors alone is expected to surpass $8.8 billion by 2027, highlighting the commercial potential of Rakovina's pipeline. The broader oncology segment continues to dominate the biopharmaceutical market due to the increasing global cancer (search) burden and rising adoption of targeted therapies.
Moving forward, Rakovina plans to leverage these findings to further refine and train its AI models, with the goal of advancing best-in-class lead candidates for both the PARP1 (search) and ATR programs into clinical development. The company intends to collaborate with pharmaceutical partners to accelerate the path to clinical trials and deliver novel therapies to patients with hard-to-treat malignancies.
The integration of AI across various stages of the biopharmaceutical process is expected to be a critical driver of growth in the sector, with the global biopharmaceutical market projected to expand from $537.54 billion in 2025 to $1.8 trillion by 2034, achieving a compound annual growth rate of 14.36%.